ZEALAND PHARMA A/S: Financial statements 2018
CVR: 20045078
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2018. In 2018, the company reported revenue of DKK 37,977,000 and a net result of DKK 581,282,000 compared with DKK -272,271,000 the year before. That is a decrease of 72.8% compared with the year before. The profit margin was 1,530.6%. Equity in the 2018 report amounted to DKK 1,116,281,000. The solvency ratio was 90.8%.
- Revenue
- DKK 37,977,000
- Profit/Loss
- DKK 581,282,000
- Equity
- DKK 1,116,281,000
- Total Assets
- DKK 1,229,797,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | 38M | - | 581.3M | 1.1B | - |
| 2017 | 139.8M | - | -272.3M | 528.5M | - |
| 2016 | 234.8M | - | -153.9M | 278.2M | - |
| 2015 | 187.7M | 165.4M | -114M | 252.2M | - |
| 2014 | 153.8M | 140M | -65M | 252.8M | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
ZEALAND PHARMA A/S has published its interim report for the period July 1, 2018 to September 30, 2018.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2018 to June 30, 2018.
ZEALAND PHARMA A/S has published its interim report for the period January 1, 2018 to March 31, 2018.
ZEALAND PHARMA A/S has published its annual report for 2017. Revenue came to DKK 139,775,000, and the net result was DKK -272,271,000.
As of April 19, 2018, Kirsten Aarup Drejer has joined the board of directors of ZEALAND PHARMA A/S.
As of April 10, 2018, Helle Haxgart has left the board of directors of ZEALAND PHARMA A/S.
As of April 10, 2018, Anne Kragh Sager has left the board of directors of ZEALAND PHARMA A/S.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
